Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder

Tobias Banaschewski, César Soutullo, Michel Lecendreux, Mats Johnson, Alessandro Zuddas, Paul Hodgkins, Ben Adeyi, Liza A. Squires, David Coghill

    Research output: Contribution to journalArticlepeer-review

    42 Citations (Scopus)

    Abstract

    Optimal management of attention deficit hyperactivity disorder (ADHD) aims not only to ameliorate patients' symptoms, but also to improve health-related quality of life (HRQL) and functioning. A pivotal, 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents in ten European countries demonstrated that the stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well-tolerated treatment for symptoms of ADHD.
    Original languageEnglish
    JournalCNS Drugs
    DOIs
    Publication statusPublished - 2013

    Fingerprint

    Dive into the research topics of 'Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder'. Together they form a unique fingerprint.

    Cite this